From Imagin Medicalís (TSX.V:IME) MD&A

 

The Technology i/Blue Imaging System used in conjunction with imaging agents

The Company has completed development of the i/Blue Imaging System Alpha B Prototype that it believes will establish a “new standard of care” for urologists and address the limitations of the current technology in the early detection of bladder cancer through endoscopes.

The development team has successfully retrofitted the original prototype with significant improvements to its internal components. Image processing and display software has been developed that integrates state-of-the art, high resolution cameras and patented, image-blending technology with other proprietary elements. The result will be a composite image highlighting the cancer lesions within the bladder in high definition, estimated to be 100 times more sensitive than currently available systems.

These advancements are expected to expose the specifics of the image in less than 15 minutes versus the full hour required by conventional fluorescence systems. Premalignant lesions and tumor tissue along the margins will be highlighted and identified for removal, potentially reducing the chances of recurrence. Producing superior imaging quality in less than one quarter of the time of current systems is expected to increase the efficiency of the operating room and reduce healthcare costs by potentially enabling follow-up exams to be performed in the less-expensive physician’s office.

In addition, the surgeon will no longer need to switch back and forth between two images. The i/Blue’s specialized cameras will employ Simultaneous Acquisition of Differing Images, a patented technology which automatically blends the white and blue light images into one, putting the cancer into context and enabling the surgeon to better visualize and resect the cancer.

The i/Blue’s patented technology can be seamlessly adapted to most endoscopes on the market today.

Benefits of the i/Blue Imaging System

• “Sees” the cancer is less than 15 minutes vs. one hour - Optics 100 times more sensitive

• No switching back and forth - Simultaneous acquisition of two different images blends the white light and fluorescence images into one

- Puts the cancer into context within the bladder

- Enables surgeon to better visualize and resect the cancer, helping to reduce recurrence

• Adapts to blue light method with added unique fluorescence wavelengths

Future Development – i/Vision Imaging System

The i/Blue Imagin System will be expanded to incorporate multiple illumination sources so that detection of different contrast agents can be realized by the same system. Such a system can be custom made or designed to accommodate the most commonly used fluorescing contrast agents, such as those currently available based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG). This instrument will enable expansion into multiple endoscopic procedures, cancerous or noncancerous conditions, such as laparoscopic (general and gynecology), colorectal, thoracic and a variety of gastroenterology procedures.

Imagin continues to work against its two-year plan that will be completed with the support of Dr. Stavros Demos, the inventor, currently a Senior Scientist and Group Leader of the Optical Materials Group at the University of Rochester Laboratory for Laser Energetics (LLE).

In Q4 of 2016, the Company completed the development of the Alpha B Prototype and expects to begin a Research Study at the University of Rochester Medical Center when hospital approvals are obtained in 2Q 2017.

Imagin hired Optel, Inc, an optical product design firm located in Rochester, New York, to design the i/Blue Imaging System for manufacturability and commercialization. Plans include reducing the size of the current prototype by 70%, enabling the i/Blue system to be used as a mobile device that can be easily moved between different operating rooms and physicians’ offices.

Imagin plans to begin the FDA approval process in Q3 of 2017, followed by additional clinical trials in Q4 at the University of Rochester as well as UC Davis Comprehensive Cancer Center in California. Once these separate, concurrent steps are completed, commercialization is planned to begin in the second half of 2018.

 

http://aheadoftheherd.com/Newsletter/2016/Mousetraps.htm

 

http://aheadoftheherd.com/Newsletter/2016/Detecting-Cancer.html

 

Rick


I own a lot of IME shares and warrants



No Charge  Newsletter Signup

 

Newsletter Unsubscribe



To contact us please email rick@aheadoftheherd.com

Ahead of the Herd
www.aheadoftheherd.com